Octave Accelerates Leadership in Precision Care with Addition of World-Class Commercial Executives More

Our Science

Powerful innovation to transform MS

We're committed to rigorous and ongoing evaluation.

Browse our latest publications below.

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS)

Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial – Interim Analysis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design

Bridging Proteomics to the Clinic – A Multivariate Blood Test for Disease Activity in Multiple Sclerosis

Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis

1 2 8

Improving Patient Outcomes Through a Comprehensive Care Platform in MOVING-MS – A Case Study

Measuring Outcomes and Value: an Integrated, Novel Solution for Generating insights in MS (MOVING MS)

Safety and Effectiveness of Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Trial – Interim Analysis

Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population

Evaluating the Impact of Manual Editing on Automated MRI Lesion Segmentation in Multiple Sclerosis

Discrepancies in the Detection of Salient MS Lesion Counts Between Neuroradiologists and Manually Corrected Automated Lesion Segmentation

Comparison of Natalizumab, Ocrelizumab, and Diroximel Fumarate in RRMs Patients Stable on Therapy to Characterize Proteomic, Radiomic, and Clinical Trajectories: Study Design

Bridging Proteomics to the Clinic – A Multivariate Blood Test for Disease Activity in Multiple Sclerosis

Disease Activity Score and Disease Pathway Scores Measured Using the Multiple Sclerosis Disease Activity Test are Significantly Reduced Prior to the Week 96 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies

Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis